Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 27;145(9):902-903.
doi: 10.1182/blood.2024027469.

Competition for CD19 binding may accelerate CAR efficacy

Alexandre V Hirayama  1 , Marie Bleakley  1
Affiliations
Editorial

Competition for CD19 binding may accelerate CAR efficacy

Alexandre V Hirayama et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.V.H. received research funding from Juno Therapeutics (a Bristol Myers Squibb company) and Nektar Therapeutics and received honoraria from Bristol Myers Squibb. M.B. is an inventor on a patent describing HA-1 T-cell receptor therapy that is licensed to Promicell Therapeutics; served on the scientific advisory board of Orca Bio; has given sponsored talks for Miltenyi Biotec; and leads a clinical trial that receives some research funding from Miltenyi Biotec.

Comment on

References

    1. Koh SK, Kim H, Han B, et al. Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis. Blood. 2025;145(9):956–969. - PubMed
    1. Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702–723. - PMC - PubMed
    1. Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024;143(3):258–271. - PMC - PubMed
    1. Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112–116. - PMC - PubMed
    1. Tschumi BO, Dumauthioz N, Marti B, et al. CART cells are prone to Fas- and DR5mediated cell death. J Immunother Cancer. 2018;6(1):71. - PMC - PubMed

LinkOut - more resources